IP Library Granted Patent US 10,337,012
Granted Patent B2
US 10,337,012 · App. 15/410,480 · Granted Jul 2, 2019

Method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells

Inventor: Takahiro Ochiya (Tokyo, JP)
Assignees: 3-D Matrix, Ltd.; National Cancer Center
C12N15/1137A61K31/7105C12Q1/6886C12Y204/99018G01N33/574G01N33/57415C12N2310/14C12N2310/3513C12N2310/531C12N2320/32C12Q2600/106C12Q2600/118C12Q2600/158G01N2333/91097
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,337,012
App. No.
15/410,480
Granted
Jul 2, 2019
Kind
B2
Abstract

The invention provides a method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells.

Claims (12)

1. A method of treating a cancer containing or derived from cancer stem cells comprising a step of administering an siRNA-carrier complex comprising an siRNA against ribophorin II (RPN2) and a transport carrier to a subject in need thereof, wherein the cancer stem cells have a mutated p53 gene, and wherein the siRNA interferes with RPN2 gene expression in an in vitro assay.

2. The method of claim 1 , wherein the transport carrier comprises the peptide AAAAAAK (SEQ ID NO: 26).

3. The method of claim 1 , wherein the siRNA-carrier complex is administered locally.

4. The method of claim 1 , wherein the siRNA-carrier complex is administered systemically.

5. The method of claim 1 , wherein a double-stranded region of the siRNA is 19 bases in length.

6. The method of claim 1 , wherein a double-stranded region of the siRNA comprises position of 1,194 of the RPN2 gene sequence (SEQ ID NO: 1).

7. The method of claim 1 , wherein a double-stranded region of the siRNA corresponds to at least position 1,212 of the RPN2 gene sequence (SEQ ID NO: 1).

8. The method of claim 1 , wherein the siRNA corresponds to positions comprises 1,194-1,212 of the RPN2 gene sequence (SEQ ID NO: 1).

9. The method of claim 1 , wherein the siRNA comprises RNA comprises SEQ ID NO: 2.

10. The method of claim 1 , wherein the siRNA comprises RNA comprising SEQ ID NO: 3.

11. The method of claim 1 , further comprising administering a substance for introducing a nucleic acid.

12. The method of claim 11 , wherein the substance for introducing a nucleic acid is liposome.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2019
From: OCHIYA, TAKAHIRO
To: NATIONALCANCER CENTER RESEARCH INSTITUTE; 3-D MATRIX, LTD.
Reel/Frame 048682/0433 →
CHANGE OF NAME Recorded Mar 24, 2019
From: NATIONAL CANCER CENTER RESEARCH INSTITUTE
To: NATIONAL CANCER CENTER
Reel/Frame 048682/0473 →
Priority Claims (1)
JP 2010-184764 · Aug 20, 2010 · national
Continuity (2)
Division 13817763
Related Publication 20170240902A1 · Aug 24, 2017
Cited By (1)
US 12,239,744